All Stories

  1. A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules

    Article • The World Journal of Biological Psychiatry, February 2019, Taylor & Francis

    Dr Gabriella Gobbi

  2. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain

    Article • Current Medicinal Chemistry, October 2018, Bentham Science Publishers

    Dr Gabriella Gobbi

  3. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors

    Article • Pharmacological Research, November 2016, Elsevier

    Dr Gabriella Gobbi

  4. Tryptophan via serotonin/kynurenine pathways abnormalities in a large cohort of aggressive inmates: markers for aggression

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, October 2016, Elsevier

    Dr Gabriella Gobbi

  5. The fatty acid amide hydrolase inhibitor URB597 modulates serotonin-dependent emotional behaviour, and serotonin1A and serotonin2A/C activity in the hippocampus

    Article • European Neuropsychopharmacology, March 2016, Elsevier

    Dr Gabriella Gobbi

  6. The Y2 receptor antagonist BIIE0246 reverses corticosterone-induced anxiogenic-related behavior and neuronal hypertrophy

    Article • Neuropeptides, February 2016, Elsevier

    Dr Gabriella Gobbi

  7. Translational Research in Suicide: Is It Possible to Study Suicide in Animal Models?

    Article • January 2016, Springer Science + Business Media

    Dr Gabriella Gobbi

  8. Valproate augmentation in a subgroup of patients with treatment-resistant unipolar depression

    Article • The World Journal of Biological Psychiatry, October 2015, Taylor & Francis

    Dr Gabriella Gobbi

  9. Antinociceptive properties of selective MT2 melatonin receptor partial agonists

    Article • European Journal of Pharmacology, October 2015, Elsevier

    Dr Gabriella Gobbi

  10. Anatomical and cellular localization of melatonin MT1and MT2receptors in the adult rat brain

    Article • Journal of Pineal Research, March 2015, Wiley

    Dr Baptiste Lacoste, Dr Gabriella Gobbi

  11. Selective melatonin MT2 receptor ligands relieve neuropathic pain through modulation of brainstem descending antinociceptive pathways

    Article • Pain, February 2015, Wolters Kluwer Health

    Dr Baptiste Lacoste, Dr Gabriella Gobbi

  12. Quetiapine in Postpartum Psychosis

    Article • Journal of Clinical Psychopharmacology, December 2014, Wolters Kluwer Health

    Dr Gabriella Gobbi

  13. Melatonin

    Article • September 2014, Taylor & Francis

    Dr Gabriella Gobbi

  14. MELATONIN: “Therapeutic Value and Neuroprotection” edited by Venkatramanujan Srinivasan, Gabriella Gobbi, Samuel D. Shillcutt and Sibel Suzen

    Article • Journal of Experimental and Clinical Medicine, September 2014, Ondokuz Mayis University

    Dr Gabriella Gobbi

  15. MT2 Melatonin Receptors: Their Role in Sleep and Neuropsychiatric Disorders

    Article • September 2014, Taylor & Francis

    Dr Gabriella Gobbi

  16. Chronic nandrolone decanoate exposure during adolescence affects emotional behavior and monoaminergic neurotransmission in adulthood

    Article • Neuropharmacology, August 2014, Elsevier

    Dr Gabriella Gobbi

  17. Electrophysiological characterization of dopamine neuronal activity in the ventral tegmental area across the light-dark cycle

    Article • Synapse, July 2014, Wiley

    Dr Gabriella Gobbi

  18. Effects of quetiapine and olanzapine in patients with psychosis and violent behavior: a pilot randomized, open-label, comparative study

    Article • Neuropsychiatric Disease and Treatment, May 2014, Taylor & Francis

    Dr Gabriella Gobbi, Dr Stefano Comai

  19. Melatonin, selective and non-selective MT1/MT2 receptors agonists: Differential effects on the 24-h vigilance states

    Article • Neuroscience Letters, February 2014, Elsevier

    Dr Stefano Comai, Dr Gabriella Gobbi

  20. Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology

    Article • Journal of Psychiatry and Neuroscience, January 2014, Canadian Medical Association (CMA)

    Dr Gabriella Gobbi, Dr Stefano Comai

  21. Sleep–wake characterization of double MT1/MT2 receptor knockout mice and comparison with MT1 and MT2 receptor knockout mice

    Article • Behavioural Brain Research, April 2013, Elsevier

    Dr Gabriella Gobbi, Dr Stefano Comai

  22. Modulation of Serotonin Firing Activity Through CB1 Agonists and FAAH Inhibitors

    Article • January 2013, Springer Science + Business Media

    Dr Gabriella Gobbi

  23. Anxiolytic effects of the melatonin MT2 receptor partial agonist UCM765: Comparison with melatonin and diazepam

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, December 2012, Elsevier

    Dr Gabriella Gobbi, Dr Stefano Comai

  24. Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway

    Article • European Neuropsychopharmacology, September 2012, Elsevier

    Dr Gabriella Gobbi

  25. Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission

    Article • Progress in Neuro-Psychopharmacology and Biological Psychiatry, July 2012, Elsevier

    Dr Gabriella Gobbi

  26. The Psychopharmacology of Aggressive Behavior

    Article • Journal of Clinical Psychopharmacology, April 2012, Wolters Kluwer Health

    Dr Gabriella Gobbi, Dr Stefano Comai

  27. The Psychopharmacology of Aggressive Behavior

    Article • Journal of Clinical Psychopharmacology, February 2012, Wolters Kluwer Health

    Dr Gabriella Gobbi, Dr Stefano Comai

  28. Characterization of serotonin neurotransmission in knockout mice: implications for major depression

    Article • Reviews in the Neurosciences, January 2012, De Gruyter

    Dr Gabriella Gobbi

  29. Adolescent amphetamine exposure elicits dose-specific effects on monoaminergic neurotransmission and behaviour in adulthood

    Article • The International Journal of Neuropsychopharmacology, November 2011, Oxford University Press (OUP)

    Dr Gabriella Gobbi

  30. Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression

    Article • September 2011, Taylor & Francis

    Dr Gabriella Gobbi

  31. M-B-035 SLEEP IN MT2 MELATONIN RECEPTOR KNOCKOUT MICE

    Article • Sleep Medicine, September 2011, Elsevier

    Dr Gabriella Gobbi, Dr Stefano Comai

  32. Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice

    Article • Psychopharmacology, November 2010, Springer Science + Business Media

    Dr Gabriella Gobbi

  33. Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and Hippocampus

    Article • Neuropsychopharmacology, June 2010, Springer Science + Business Media

    Dr Gabriella Gobbi

  34. Spadin, a Sortilin-Derived Peptide, Targeting Rodent TREK-1 Channels: A New Concept in the Antidepressant Drug Design

    Article • PLoS Biology, April 2010, PLOS

    Dr Gabriella Gobbi

  35. Chronic exposure to cannabinoids during adolescence but not during adulthood impairs emotional behaviour and monoaminergic neurotransmission

    Article • Neurobiology of Disease, March 2010, Elsevier

    Dr Gabriella Gobbi

  36. N‐(Anilinoethyl)amides: Design and Synthesis of Metabolically Stable, Selective Melatonin Receptor Ligands

    Article • ChemMedChem, September 2009, Wiley

    Dr Gabriella Gobbi

  37. Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, September 2009, Springer Science + Business Media

    Dr Gabriella Gobbi

  38. The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants

    Article • Trends in Pharmacological Sciences, September 2009, Elsevier

    Dr Gabriella Gobbi

  39. Mirtazapine and paroxetine in major depression: A comparison of monotherapy versus their combination from treatment initiation

    Article • European Neuropsychopharmacology, July 2009, Elsevier

    Dr Gabriella Gobbi

  40. Endocannabinoids in the Treatment of Mood Disorders: Evidence from Animal Models

    Article • Current Pharmaceutical Design, May 2009, Bentham Science Publishers

    Dr Gabriella Gobbi

  41. Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress

    Article • European Neuropsychopharmacology, March 2009, Elsevier

    Dr Gabriella Gobbi

  42. Monoaminergic Changes in Locus Coeruleus and Dorsal Raphe Nucleus Following Noradrenaline Depletion

    Article • Neurochemical Research, February 2009, Springer Science + Business Media

    Dr Gabriella Gobbi

  43. Brain TRPV1: a depressing TR(i)P down memory lane?

    Article • Trends in Pharmacological Sciences, December 2008, Elsevier

    Dr Gabriella Gobbi

  44. The cannabinoid CB1receptor and the endocannabinoid anandamide: possible antidepressant targets

    Article • Expert Opinion on Therapeutic Targets, October 2008, Informa Healthcare

    Dr Gabriella Gobbi

  45. An index of 5-HT synthesis changes during early antidepressant treatment: α-[11C]methyl-l-tryptophan PET study

    Article • Neurochemistry International, March 2008, Elsevier

    Dr Gabriella Gobbi

  46. N-(Substituted-anilinoethyl)amides: Design, Synthesis, and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands

    Article • Journal of Medicinal Chemistry, December 2007, American Chemical Society (ACS)

    Dr Gabriella Gobbi

  47. Unusually mild tuberous sclerosis phenotype is associated withTSC2R905Q mutation

    Article • Annals of Neurology, November 2006, Wiley

    Dr Gabriella Gobbi

  48. Efficacy of Topiramate, Valproate, and Their Combination on Aggression/Agitation Behavior in Patients With Psychosis

    Article • Journal of Clinical Psychopharmacology, October 2006, Wolters Kluwer Health

    Dr Gabriella Gobbi

  49. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype

    Article • Nature Neuroscience, August 2006, Springer Science + Business Media

    Dr Gabriella Gobbi

  50. Sodium- and magnesium-valproate in vivo modulate glutamatergic and GABAergic synapses in the medial prefrontal cortex

    Article • Psychopharmacology, February 2006, Springer Science + Business Media

    Dr Gabriella Gobbi

  51. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: Comparison with antidepressant drugs

    Article • Peptides, August 2005, Elsevier

    Dr Gabriella Gobbi

  52. Serotonin Firing Activity as a Marker for Mood Disorders: Lessons from Knockout Mice

    Article • January 2005, Elsevier

    Dr Gabriella Gobbi

  53. Neurochemical and Psychotropic Effects of Bupropion in Healthy Male Subjects

    Article • Journal of Clinical Psychopharmacology, June 2003, Wolters Kluwer Health

    Dr Gabriella Gobbi

  54. Clonidine fails to modify dopaminergic neuronal activity during morphine withdrawal

    Article • Psychopharmacology, October 2001, Springer Science + Business Media

    Dr Gabriella Gobbi

  55. Clozapine blocks dopamine, 5-HT2 and 5-HT3 responses in the medial prefrontal cortex: an in vivo microiontophoretic study

    Article • European Neuropsychopharmacology, December 1999, Elsevier

    Dr Gabriella Gobbi

  56. Alterations of the thalamo-cortical system in rats prenatally exposed to ethanol are prevented by concurrent administration of acetyl- l-carnitine

    Article • Brain Research, November 1995, Elsevier

    Dr Gabriella Gobbi